REG - J.P. Morgan SE - Stabilisation Notice

MHP SEAnnouncement

22/01/2026 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260122:nRSV9542Pa&default-theme=true

RNS Number : 9542P  J.P. Morgan SE  22 January 2026

22(nd) January 2026

Not for distribution, directly or indirectly, in or into the United States or
any jurisdiction in which such distribution would be unlawful.

MHP Lux S.A.

 

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 21(st) January
2026, J.P. Morgan SE, (contact: Rishik Arya +442071342468) hereby gives notice
that no stabilisation (within the meaning of Article 3.2(d) of the Market
Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct
Authority) was undertaken by the Stabilisation Manager(s) named below in
relation to the offer of the following securities.

 Issuer:                    MHP Lux S.A.
 Guarantor (if any):        MHP Europe Limited, MHP SE, PrJSC "Zernoprodukt MHP", PrJSC "MHP",  PrJSC
                            "Agrofort", PrJSC "Oril-Leader", PrJSC "Myronivska Pticefabrika", "SPF
                            "Urozhay" LLC, "Starynska Ptahofabryka" ALLC, "Vinnytska Ptakhofabryka" LLC,
                            "Katerinopolskiy Elevator" LLC
 Aggregate nominal amount:  USD 450M
 Description:               USD 3.5NC2, Senior Unsecured Guaranteed Notes, REGS/144A

                            Listing: Euronext Dublin
 Stabilisation Manager(s):  JP Morgan SE (Stabilisation coordinator)
 Offer price:               100% / 10.5%

 

This announcement is for information purposes only and does not constitute an
invitation or offer to underwrite, subscribe for or otherwise acquire or
dispose of any securities of the Issuer in any jurisdiction

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STAFIFLALEIFFIR



            Copyright 2019 Regulatory News Service, all rights reserved